Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601489 | 0.81 | LMNA (0.41) | CYP3A4S100A4TSHRALDH1A1TDP1 | |
| SCHEMBL22601374 | 0.74 | MAPT (0.35) | CYP3A4S100A4TSHRALDH1A1TDP1 | |
| SCHEMBL22601485 | 0.70 | TNKS (0.41) | CYP3A4S100A4TSHRALDH1A1TDP1 | |
| SCHEMBL22601481 | 0.69 | CYP3A4 (0.35) | CYP3A4S100A4MAPTLMNAPOLB | |
| SCHEMBL22601486 | 0.66 | — | — | |
| SCHEMBL11624645 | 0.65 | S100A4 (0.48) | CYP3A4S100A4TSHRALDH1A1TDP1 | |
| SCHEMBL25873158 | 0.64 | LMNA (0.47) | CYP3A4ALDH1A1MAPTLMNAPOLB | |
| SCHEMBL1687993 | 0.63 | GPR3 (0.54) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL15945929 | 0.62 | CYP1B1 (0.46) | CYP3A4TSHRALDH1A1TDP1HPGD | |
| SCHEMBL3466137 | 0.62 | KMT2A (0.44) | CYP3A4S100A4TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | INTS9, INF2, CYBA | CYP3A4 265/4885S100A4 1936/4885TSHR 4200/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | CYP3A4 3999/4885S100A4 864/4885TSHR 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.